Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO), Ministry of Health, India for use in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO), Cipla added.
At around 10.05 AM, Cipla was trading at Rs 894.45 per piece up by Rs 11.50 or 1.30 percent on Sensex.
Source link
